Baumann Marcus, Hermans J J Rob, Janssen Ben J A, Peutz-Kootstra Carine, Witzke Oliver, Heemann Uwe, Smits Jos F M, Boudier Harry A J Struijker
Department of Pharmacology and Toxicology, University Maastricht, The Netherlands.
J Hypertens. 2007 Dec;25(12):2504-11. doi: 10.1097/HJH.0b013e3282ef84f8.
We previously demonstrated that when the renin-angiotensin system (RAS) is transiently blocked by an angiotensin receptor blocker (ARB) in young spontaneously hypertensive rats (SHR), this results in a prolonged blood pressure decrease and protection against target organ damage. Aldosterone is an essential hormone in the RAS, and contributes to pathologic remodeling. Thus, part of the protective effects of the ARB may be due to inhibition of aldosterone-mediated effects. To test this hypothesis, in young SHR, we compared the effectiveness of transient treatment with the mineralocorticoid receptor blocker spironolactone with those obtained by the ARB losartan.
SHR were transiently (i.e. between 4-8 weeks of age) treated with spironolactone (SHR-Spiro: 1 mg/kg per day), losartan (SHR-Los: 20 mg/kg per day) or saline. Rats were followed up until week 72 of age and cardiovascular parameters were repeatedly assessed by echocardiography, radiotelemetry of blood pressure and 24-h urine collection. End-point measurements included direct left ventricular contractility and relaxation, as well as cardiac and renal histomorphology.
Transient spironolactone treatment reduced blood pressure up to 36 weeks of age and cardiac and renal collagen deposition and tubular atrophy up to 72 weeks of age compared to untreated SHR. Pulse pressure was higher in SHR-Spiro compared to SHR-Los. Cardiac hypertrophy, albuminuria and glomerulosclerosis were not attenuated in SHR-Spiro compared to untreated SHR up to 72 weeks of age, whereas the effects in SHR-Los were ameliorated.
Although transient spironolactone treatment leads to prolonged blood pressure reduction and reduced collagen deposition, long-term organ protection only partially exists. Thus, transient spironolactone treatment is less effective than transient losartan treatment.
我们之前证明,在年轻的自发性高血压大鼠(SHR)中,当肾素-血管紧张素系统(RAS)被血管紧张素受体阻滞剂(ARB)短暂阻断时,会导致血压长时间下降,并预防靶器官损伤。醛固酮是RAS中的一种重要激素,参与病理重塑。因此,ARB的部分保护作用可能归因于对醛固酮介导效应的抑制。为了验证这一假设,在年轻的SHR中,我们比较了用盐皮质激素受体阻滞剂螺内酯进行短暂治疗与用ARB氯沙坦治疗的效果。
SHR在4至8周龄期间被短暂给予螺内酯(SHR-Spiro:每天1毫克/千克)、氯沙坦(SHR-Los:每天20毫克/千克)或生理盐水。对大鼠进行随访直至72周龄,并通过超声心动图、血压无线电遥测和24小时尿液收集反复评估心血管参数。终点测量包括直接左心室收缩和舒张功能,以及心脏和肾脏组织形态学。
与未治疗的SHR相比,短暂螺内酯治疗可使血压在36周龄前降低,心脏和肾脏胶原沉积以及肾小管萎缩在72周龄前减轻。与SHR-Los相比,SHR-Spiro的脉压更高。与未治疗的SHR相比,直至72周龄时,SHR-Spiro中的心脏肥大、蛋白尿和肾小球硬化并未减轻,而SHR-Los中的这些效应有所改善。
虽然短暂螺内酯治疗可导致血压长时间降低和胶原沉积减少,但长期器官保护仅部分存在。因此,短暂螺内酯治疗不如短暂氯沙坦治疗有效。